Investigational Drug Information for glepaglutide
What is the development status for investigational drug glepaglutide?
glepaglutide is an investigational drug.
There have been 9 clinical trials for glepaglutide.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 25th 2025.
The most common disease conditions in clinical trials are Short Bowel Syndrome, Syndrome, and Intestinal Diseases. The leading clinical trial sponsors are Zealand Pharma and [disabled in preview].
There are forty US patents protecting this investigational drug.
Summary for glepaglutide
| US Patents | 40 |
| International Patents | 0 |
| US Patent Applications | 89 |
| WIPO Patent Applications | 33 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 1 (2025-11-25) |
| Vendors | 3 |
Recent Clinical Trials for glepaglutide
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety Evaluation of Glepaglutide in Treatment of SBS | Zealand Pharma | PHASE3 |
| Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS | Zealand Pharma | PHASE3 |
| The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome | Zealand Pharma | Phase 3 |
Clinical Trial Summary for glepaglutide
Top disease conditions for glepaglutide
Top clinical trial sponsors for glepaglutide
US Patents for glepaglutide
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| glepaglutide | ⤷ Start Trial | AMPK activators | Kallyope Inc | ⤷ Start Trial |
| glepaglutide | ⤷ Start Trial | Releasable GLP-1 conjugates | QuiaPEG Pharmaceuticals AB | ⤷ Start Trial |
| glepaglutide | ⤷ Start Trial | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | RP Scherer Technologies LLC | ⤷ Start Trial |
| glepaglutide | ⤷ Start Trial | AMPK activators | Kallyope Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
